Mpox-related datasets

# Small Molecule Protein Assembly Modulators with Pan-Cancer Therapeutic Efficacy [https://doi.org/10.5061/dryad.k3j9kd5hf](https://doi.org/10.5061/dryad.k3j9kd5hf) **File description:** Each tab in the Excel file contains the raw data corresponding to a specific figure. Tabs are labeled according to the figure number, with supplemental figures indicated by an 's' before the number. In this Excel file, cells containing "n/a" represent missing or unavailable data for that particular entry. **Tab descriptions:** **Figure 1** 1A- shows assessment of the endogenous apoptosis response in multiple cell lines. Plates were seeded with LNCaP C-33, LNCaP C-81, CHO K-1, and Hennes 20 cells. After three days of growth Apo-ONE reagent was added and caspase-3/7 activity was determined by fluorescent readout. Excel document contains F521 absorbance (RFU) values for each cell line. 1D and 1E- show activity of PAV-617 and PAV-951 in the Hennes 20 “arrest of proliferation” assay where parallel plates of Hennes 20 cells were seeded at a high density of 15,000 cells per well and a low density of 500 cells per well and treated with DMSO, PAV-617, or PAV-951. Fluorescent reading (RFU) corresponding to cell viability was calculated using an AlamarBlueTM assay. The average absorbance of three wells containing only media was subtracted from the absorbance values of the vehicle and treatment groups. The resulting values were then divided by the average absorbance of six vehicle wells to calculate the percentage growth, shown in the excel document. 1F, 1G,1H, and 1I- show recovery of cancer cell growth following removal of compound. Hennes 20 or LNCaP C-33 cells were seeded at a low density and then incubated with DMSO, PAV-617, or PAV-951. After a period of treatment, the medium containing compound was removed and replaced with fresh media. Plates were assessed for cell viability by AlamarBlueTM on day 5, 8, 11, and 14. Excel document contains F590 absorbance (RFU) for vehicle and drug treated cells on each day. **Figure 2** 2A- shows activity of PAV-617 against MPXV. BSC-40 cells were infected with 100 plaque forming units of MPXV Zaire 79 and treated with PAV-617 for three days. In the excel document plaques observed are shown as a percentage of the plaques observed in untreated cells. 2B- shows activity of PAV-951 against HIV. MT-2 cells were infected with NL4-3 Rluc HIV and treated with PAV-951 for four days. In the excel document plaques observed are shown as a percentage of the plaques observed in untreated cells. **Figure 3** 3A- shows the percentage growth values of PAV-617 and PAV-951 assessed in house against A549, HT29, LNCaP C-33, and PANC-1 cell lines. These values were used to calculate the IC50’s shown in figure 3A of the paper. 3B- shows the average percentage growth values of PAV-617 and PAV-951 in the Eurofins OncoPanel against A172, BFTC-905, COR-L105, DB, FaDu, H9, Hs 294T, MCF7, MDA MB 436, MeWo, MHH-PREB-1, SJSA1-OSA, SW1353, U2OS, HMEC, and HUVEC cell lines. 3C- shows the mean optical density and percentage growth of PAV-617 and PAV-951 in the NCI-60 screen against CCRF-CEM, HL-60(TB), K-562, MOLT-4, RPMI-8226, SR, A549/ATCC, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, NCI-H322M, NCI-H460, NCI-H522, COLO 205, HCC-2998, HCT-116, HCT-15, HT29, KM12, SW-620, SF-268, SF-295, SF-539, SNB-19, SNB-75, U251, LOX IMVI, MALME-3M, M14, MDA-MB-435, SK-MEL-2, SK-MEL-28, SK-MEL-5, UACC-257, UACC-62, IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, NCI/ADR-RES, SK-OV-3, 786-0, A498, ACHN, CAKI-1, RXF 393, SN12C, TK-10, PC-3, DU-145, MCF7, MDA-MB-231/ATCC, HS 578T, BT-549, T-47D, MDA-MB-468 cell lines. These values were used by the NCI to calculate the IC50s and LC50s shown in figure 3C. 3D- shows the percentage growth values of PAV-617 and PAV-951 assessed on HMEC and HUVEC cell lines. **Figure 4** 4A- shows tumor volume (mm3) across time for an A549 lung cancer treated with vehicle, PAV-617, or Gemcitabine hydrocholoride. 4B- shows tumor volume (mm3) across time for a A549 lung cancer treated with vehicle, PAV-951, or Gemcitabine hydrochloride. 4C- shows tumor volume (mm3) across time for a HT-29 colorectal cancer treated with vehicle, PAV-951, or Irinotecan. **Figure 5** 5A, 5B, and 5C- shows optical density of various proteins western blots. **Figure 6** 6- growth percentages of PAV-541, PAV-621, PAV-951, and PAV-436 tested on the NCI-60 assay by the NCI. **Supplemental figures** s3- shows the percentage growth values of PAV-951, PAV-621, and gemcitabine against MRC5 and A549 cells. Fluorescent reading (RFU) corresponding to cell viability was calculated using an AlamarBlueTM assay. The average absorbance of three wells containing only media was subtracted from the absorbance values of the vehicle and treatment groups. The resulting values were then divided by the average absorbance of six vehicle wells to calculate the percentage growth, shown in the excel document. s7.1- shows safety data from an 11-day body weight study of mice treated with either a vehicle or 2.5 mg/kg PAV-951 s7.2- shows hematology of the treated mice upon completion of the study. s7.3- shows the concentration of PAV-951 or PAV-621 in the blood or lung of CD1 (PAV-951) or balb/c nude mice (PAV-621) following a single IV or IP injection. s7.4- show the concentration of PAV-617 and PAV-951 in rats following a single IV or IP dose of compound. s8A- shows spectral counts of proteins detected by MSMS in DRAC eluates from the PAV-617 resin under cold or hot conditions, as well as from the methylene blue resin and the negative control resin. s8B- shows spectral counts of proteins detected in the PAV-951 and PAV-621 resin eluates, as well as negative control resins eluted with PAV-951 and PAV-621. s9- shows optical density of ALDH1A1 western blot. s10- shows the percentage growth values of PAV-951, PAV-621, and gemcitabine against A549 cells at different treatment times. A549 cells were plated at a concentration of 2,500 cells/well and treated with 0.1uM, 0.5uM, 2.5uM or 12.5uM compound or vehicle concurrently with plating (“time 0”) or 24 hours later. After 72 hours, cell viability was measured by an AlamarBlueTM assay.

Poxviruses are large cytosolic DNA viruses with a propensity to cause zoonoses. They are present in animal reservoirs and responsible for a large spectrum of disorders, including human smallpox. Only few causative treatment options are available, but vaccination with the non-pathogenic vaccinia virus enabled the eradication of the smallpox-causing variola virus. However, the herd immunity against poxviruses is dwindling in humans. Accordingly, poxviruses including monkeypox virus are considered as potentially highly threatening for their pandemic ‘spillover’ risk. Here, we strive to develop novel virostatics for the fight of poxviral dieases. Our approach is based on a set of atomic resolution cryo EM structures of vaccinia transcription complexes that we have recently determined. We use in silico screening to identify novel binders, test them in a radionuclide transcription assay for inhibition and will characterize the resulting ligand-RNA polymerase complexes by cryo EM.

This dataset introduces a novel collection of Instagram posts related to Monkeypox, focusing on anxiety detection in Bangla language. Due to the scarcity of publicly available data on Monkeypox reactions in Bangla, around 2,000 posts, including 638 Bangla posts and 1,362 English posts (translated into Bangla), were gathered from hashtags like #Monkeypox, #Mpox, and others. The posts, published between January and July 2024, were labeled into two classes—non-anxiety and anxiety—verified by professional psychologists. The final dataset contains 791 anxiety samples and 783 non-anxiety samples, offering a balanced resource for further research.

Infectious diseases such as Monkeypox have continued to pose significant threats to global health, demanding effective strategies for prevention and control. Existing studies have primarily focused on Monkeypox clinical analysis, with less attention given to adopting indigenous language as a health communication for the proper behavioural practices. This study investigated the usage of indigenous language as a health communication strategy towards the prevention of Monkeypox vis-à-vis the knowledge, attitude, and practices of Alimosho residents of Lagos State. Furthermore, the study determines the influence of information sources on resident’s behavioural practices. The research employed a mixed-methods approach of in-depth interviews and surveys to collect data from public health practitioners and 439 randomly selected residents of Alimosho using multistage sampling. Findings revealed a mixed level of understanding and adherence to recommended preventive measures. The study revealed that little effort was channelled into raising awareness about Monkeypox especially as it involved using the indigenous language. The hospital focused mainly on Hepatitis B virus, Hepatitis C virus, HIV, and Smallpox by employing communication channels such as seminars, flyers and use the media. The study also showed that majority of the respondents (83%) were aware of Monkeypox; however, only 20.4% were knowledgeable about the symptoms, mode of transmission, and preventive measures towards the disease. This study concludes that there is poor knowledge regarding Monkeypox amongst Alimosho residents despite seeking information on the disease. Therefore, the study further recommends that indigenous language should be adopted alongside the various communication channels used by the Government as well as Non-governmental organisations towards orienting Alimosho residents about Monkeypox right behavioural practices.

Datos de 2 507 artículos extraidos de SCOPUS sobre viruela del mono o viruela símica, publicados en el periodo 2001-2023.

Data doc. contains empty form about obtaining written permission from participants, allowing the researcher to conduct literature searches, retrieve pertinent data, do analysis, and contribute to the preparation of papers for systematic review studies.

Supplementary Figure 1. Clinical photographs of a 38-year-old female with multiple pink, tender dome-shaped indurated papulovesicles scattered on the face (A) and arms (B) in the emergency room.

The 2022 mpox virus outbreak was sustained by human-to-human transmission, however it is currently unclear which factors lead to sustained transmission of mpox virus (MPXV). Here, we present Mastomys natalensis as a model for MPXV transmission after intraperitoneal, rectal, vaginal, aerosol, and transdermal inoculation with an early 2022 human outbreak isolate (Clade IIb). Virus shedding and tissue replication was route-dependent and occurred in the presence of self-resolving localized skin, lung, reproductive tract, or rectal lesions. Mucosal inoculation via rectal, vaginal and aerosol routes led to increased shedding, replication and a proinflammatory T-cell profile compared to skin inoculation. Contact transmission was higher from rectally inoculated animals. This suggests that transmission might be sustained by increased susceptibility of the anal and genital mucosae for infection and subsequent virus release.

Monkeypox (mpox) is a rare disease that is caused by infection with monkeypox (mpox) virus. This virus can spread to anyone through close, personal, often skin-to-skin contact. The mpox genome is a large single linear molecule of dsDNA, about 197 kilobase-pairs (kbp) in length. The genome consists of about 190 non-overlapping open reading frames (>180 bp long) containing 60 or more amino acid residues. There are two clades of Mpox: the West African clade (clade II) and the Congo Basin clade (clade I). The QuantiVirus™ MPXV Test Kit [FDA EUA and CE/IVD] detects DNA from both clade I and clade II of MPXV in lesion swab specimens (i.e., swabs of acute pustular or vesicular rash). It uses a fluorescent probe with specific primer sets to detect the J2L and B6R genes within the genome of MPXV. Primers and probe for an internal control, RNase P are also integrated in the assay to validate the assay quality.

Abstract Background Monkeypox (Mpox) virus infection is a topic of growing interest today because of its potential public health impact and concern about possible outbreaks. Reliable and up-to-date sources of information that provide accurate data on its transmission, symptoms, prevention, and treatment are essential for understanding and effectively addressing this disease. Therefore, the aim of the present study is to determine the prevalence of sources of information on Mpox virus infection. Methods An exhaustive systematic review and meta-analysis was carried out using the information available in the PubMed, Scopus, Web of Science, Embase, and ScienceDirect databases up to August 3, 2023. The data were analyzed using R software version 4.2.3. The quality of the cross-sectional studies that formed part of this review was assessed using the Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) tool. In addition, a subgroup analysis was performed based on the study populations. Results Through electronic searches of five databases, a total of 1833 studies were identified. Twenty-four cross-sectional articles were included, with a total sample of 35,959 participants from 34 countries. The pooled prevalence of each of the included information sources was: social networks reached 59% (95% CI: 50–68%; 29,146 participants; 22 studies; I2 = 100%; p < 0.01); the Internet was 61% (95% CI: 44–77%; 14,002 participants; 5 studies; I2 = 100%; p < 0.01), radio reached 10% (95% CI: 07–13%; 8917 participants; 4 studies; I2 = 93%; p < 0.01), television accounted for 24% (95% CI: 09–43%; 14,896 participants; 8 studies; I2 = 100%; p < 0.01), and the combination of radio and television accounted for 45% (95% CI: 31–60%; 4207 participants; 7 studies; I2 = 99%; p < 0.01); for newspapers, it was 15% (95% CI: 05–27%; 2841 participants; 6 studies; I2 = 99%; p < 0.01), friends and relatives accounted for 19% (95% CI: 12–28%; 28,470 participants; 19 studies; I2 = 100%; p < 0.01), the World Health Organization (WHO) accounted for 17% (95% CI: 07–29%; 1656 participants; 3 studies; I2 = 97%; p < 0.01), the Centers for Disease Control and Prevention (CDC) accounted for 10% (95% CI: 03–21%; 2378 participants; 3 studies; I2 = 98%; p < 0.01), and the combination of WHO and CDC websites accounted for 60% (95% CI: 48–72%; 1828 participants; 4 studies; I2 = 96%; p < 0.01), and finally, scientific articles and journals accounted for 24% (95% CI: 16–33%; 16,775 participants; 13 studies; I2 = 99%; p < 0.01). Conclusion The study suggests that people access a variety of information sources to gain knowledge about Mpox virus infection, with a strong emphasis on online sources such as social networks and the Internet. However, it is important to note that the quality and accuracy of information available from these sources can vary, underscoring the need to promote access to reliable and up-to-date information about this disease to ensure public health.